Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06266299 2026-01-28

A Study of KK2269 in Adult Participants With Solid Tumors

101 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

BreastGenitourinaryHead & NeckThoracic

51 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT06576635 2026-01-20

LUNG-05

Phase NA Recruiting

29 enrolled

NSCLC

NCT07306624 2026-01-15

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

300 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

31 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04794699 2025-11-12

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

180 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT05142189 2025-11-12

LuCa-MERIT-1

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06228326 2025-10-24

KYANITE-1

250 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06745908 2025-10-21

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

BreastDermatologicGastrointestinalHead & NeckThoracic

40 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT07070440 2025-08-29

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07050043 2025-07-03

LEDANG

123 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05910827 2025-06-22

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

98 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT06929936 2025-06-08

PROTECT-1

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06382129 2025-05-02

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

680 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05800587 2025-04-04

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

22 enrolled

Lung Neoplasms

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06300177 2024-04-26

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

522 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02889666 2024-04-17

CCODG-NSCLC

500 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05777278 2023-10-10

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

29 enrolled